A study on HSLG-032303 capsules in treating Low Libido in adult males.

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Male subjects aged 21 to 50 years with general good health.

2.Healthy subjects as determined by the investigator based on a medical evaluation including medical history, physical and laboratory examinations.

3.Subjects with Sexual Desire Inventory (SDI) Scale score 45 or lower indicating low sexual desire/ low libido.

4.Subjects willing to sign an informed consent document.

5.Subjects willing to adhere to protocol requirements throughout the study period.

6.Subjects who have not participated in any clinical study in the past 30 days.

Exclusion Criteria

1.Subjects with known clinically significant cardiovascular, neurological, respiratory, gastrointestinal, genitourinary, congenital or any other disorder as determined by the investigator that may interfere with the study outcome or put the subjects in medical risk.

2.Subjects with any other sexual disorders like Erectile Dysfunction (ED), Pre-Mature Ejaculation (PME) or subjects taking any other medications like vasodilators, PDE-5 inhibitors, prostaglandins, or any other herbal or dietary supplement for sexual wellness within past one month.

3.Subject with any other significant cause of low libido like social, personal, or cultural which in the opinion of the investigator may interfere with the study results.

4.Subjects with known history or present condition of allergic response to the study drug or any ingredients in the investigational product.

5.Pre-existing systemic diseases (auto immune disorders, hormonal replacement, etc.) necessitating long-term medications.

6.Male subjects who refrain to use adequate contraception and donate sperm from first admission to the study until 90 days after the follow-up visit.

7.Known alcohol or any other substance abuse according to DSM-V criteria

8.Any other reason (physical, psychological, or social) that can interfere with the subject’s compliance to the study in the opinion of the Investigator.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy Endpoints <br/ ><br>•Number of subjects showing improvement and/or improvement in mean Sexual Desire Inventory (SDI) scale score from baseline (day1) to EOS (day28). <br/ ><br>•Number of subjects showing improvement and/or mean improvement in each symptom of Aging Male Symptoms Scale (AMS) score from baseline to EOS.Timepoint: Day 1 And Day 28

Secondary Outcome Measures

Name	Time	Method
Safety Endpoints <br/ ><br>•General Physical Examinations & Vital Signs. <br/ ><br>•Laboratory Examinations. (Appendix-1) <br/ ><br>•Incidence of adverse events during the study period. <br/ ><br>•Proportion of subjects withdrawing from trial because of adverse events (tolerability).Timepoint: Day1 & Day28